Use of tigecycline at a teaching hospital

Main Article Content

Gleycivane Nunes da Silva
Erivaldo Elias Junior
Vanessa Marcon de Oliveira
Erica Freire de Vasconcelos Pereira
Cristiane Munaretto Ferreira
Bianca Rodrigues Acacio
Vanessa Terezinha Gubert
Maria Tereza Ferreira Duenhas Monreal

Abstract

Introduction: Tigecycline is an antimicrobial agent, approved for the treatment of complicated skin and soft tissue infections, hospital-acquired and community-acquired pneumonia, intra-abdominal infections and anaerobic or atypical infections. Objective: To describe the use of tigecycline in a teaching hospital and to compare data from patients who had their prescriptions audited by the hospital infection committee with those who did not have audited prescriptions. Methods: Retrospective observational cohort study conducted at a teaching hospital from April 2012 to March 2014 including patients who received tigecycline. Demographic variables, comorbidities, microbiological findings, prescribed antibiotics and technical opinions issued by the Hospital Infection Control Service were collected. Results: 71 patients were included, aged between 13 and 92 years, 63.4% were male and 56.3% were non-white. Tigecycline was the first antimicrobial choice in 19.7% (14/71) of the cases, while the use associated with other antibiotics was observed in 66.2% (45/71) of the prescriptions. mainly with meropenem (28.9%). Empirical use was performed in 69.0% of cases, after culture and the antibiogram in 31.0% and off label use in 81.7%. The microorganisms frequently identified by the culture tests were Enterococcus faecalis (17.6%), Pseudomonas aeruginosa (14.7%) and Klebsiella penumoniae (11.8%). Conclusion: The study demonstrated that empirical and off label use is common in clinical practice and few prescriptions were guided by the results of the culture and the antibiogram, demonstrating the need for prescribers to evaluate the benefits/ risks of using this antibiotic, risk of resistance, adverse effects and drug interactions, in addition to cost.

Downloads

Download data is not yet available.

Article Details

How to Cite
Silva, G. N. da, Elias Junior, E., Oliveira, V. M. de, Pereira, E. F. de V., Ferreira, C. M., Acacio, B. R., Gubert, V. T., & Monreal, M. T. F. D. (2022). Use of tigecycline at a teaching hospital. ABCS Health Sciences, 47, e022202. https://doi.org/10.7322/abcshs.2020090.2030
Section
Original Articles

References

1. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470-80. https://doi.org/10.1093/jac/dki248

2. Frampton JE, Curran MP. Tigecycline. Drugs. 2005;65(18):2623-35. https://doi.org/10.2165/00003495-200565180-00008

3. Rosa FG, Corcione S, Di Perri G, Scaglione F. Re-trailing Tigecycline Therapy. New Microbiol. 2015;38(2):121-36.

4. Baadani AM, Thawadi SI, El-Khizzi NA, Omrani AS. Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi Med J. 2013;34(3):248-53.

5. Dhabaan GN, AbuBakar S, Shorman MA, Hassan H. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia. J Chemother. 2012;24(2):87-92. https://doi.org/10.1179/1120009X12Z.00000000017

6. Barberàn J, Salso S, Alhambra A. Tigecycline: 10 years of history and still in full force. Rev Esp Quimioter. 2015;28(2):61-78.

7. Ulu-Kilic A, Alp E, Altun D, Cevahir F, Kalin G, Demiraslan H. Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use. J Infect Dev Ctries. 2015;9(3):309-12. https://doi.org/10.3855/jidc.4700

8. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963-71. https://doi.org/10.1093/jac/dkr242

9. Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8.

10. Curcio D, Vargas SW, Ubiergo SG, Varón F, Suarez JR, Chavez CP, et al. Tigecycline treatment of critically ill patients: the LatinUser experience. Curr Clin Pharmacol. 2011;6(1):18-25. https://doi.org/10.2174/157488411794941304

11. Curcio D, Fernández F, Cané A, Barcelona L, Stamboulian D; The Tigecycline Initial Use Registry Group. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis. 2008;12(3):198-201. https://doi.org/10.1590/S1413-86702008000300007

12. Curcio D, Fernandez F, Duret F. [Initial use of tigecycline in Argentina]. Rev Chilena Infectol. 2007;24(6):497-9. http://dx.doi.org/10.4067/S0716-10182007000600012

13. Basseti M, Eckmann C, Boadmann KF, Dupont H, Heizmann WR, Montravers P, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68(Suppl 2):ii5-14. https://doi.org/10.1093/jac/dkt140

14. Eckmann C, Montravers P, Basseti M, Bodmann KF, Heizmann WR, García MS, et al. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68(Suppl 2):ii25-35. https://doi.org/10.1093/jac/dkt142

15. Monstravers P, Basseti M, Dupont H, Eckmann C, Heizmann WR, Guirao X, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemothe. 2013;68(Suppl 2):ii15-24. https://doi.org/10.1093/jac/dkt141

16. Rossi F. The challenges of antimicrobial resistance in Brazil. Clin Infect Dis. 2011;52(9):1138-43. https://doi.org/10.1093/cid/cir120

17. Alvarez-Lerma F, Blanco L, Rodríguez JA, Grau S, Conde-Estévez D, Luque S. Differences in the use of tigecycline between ICU patients and non-ICU patients. Rev Esp Quimioter. 2010;23(2):63-71.

18. Curcio D, Alí A, Duarte A, Pauta AD, Ibáñez-Guzmán C, Sang MC et al. Prescription of antibiotics in intensive care units in Latin America: an observational study. J Chemother. 2009;21(5):527-34. https://doi.org/10.1179/joc.2009.21.5.527

19. González-del Castillo J, Domínguez-Bernal C, Gutiérrez-Martín MC, Núñez-Orantos MJ, Candel FJ, Martín-Sánchez FJ. Efecto de la inadecuación de la antibioterapia en Urgencias sobre la eficiencia en la hospitalización. Enferm Infec Microb Clín. 2017;35(4):208-213. https://doi.org/10.1016/j.eimc.2015.10.005

20. Montravers P, Dupont H, Bedos JP, Bret P; Tigecycline Group. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med. 2014;40(7):988-97. https://doi.org/10.1007/s00134-014-3323-7

21. Heizmann WR, Löschmann PA, Eckmann C, von Eiff C, Bodmann KF, Petrik C. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37-43. https://doi.org/10.1007/s15010-014-0691-4

22. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis. 2010;10:287. https://doi.org/10.1186/1471-2334-10-287

23. U. S. Food and Drug Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections [internet] 2013. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-antibiotics.

24. Wang J, Pan Y, Shen J, Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2017;16:24. https://doi.org/10.1186/s12941-017-0199-8